Dobson | Davanzo Assesses the Financial Impact of 340B Discounts on Drug Manufacturers

Published Monday, September 25, 2017

Al Dobson, Kennan Murray and Joan DaVanzo recently co-authored a report for 340B Health summarizing an analysis that assessed the financial impact of 340B discounts on drug manufacturers and evaluated the plausibility of claims that the 340B Program is a cause of pharmaceutical price increases, cost shifting, and reductions in private sector research and medical discovery. The analysis found that the 340B Program cannot plausibly be a major driver of U.S. drug spending or a major cause of cost shifting by drug manufacturers to make up for 340B discounts. The results of this analysis were published on the 340B Health website to view click here.